The success of the anti-glaucoma drug development pipeline depends on the success of basic and preclinical studies. In preclinical trials, we can perform in vivo studies in animal subjects. In vivo studies can demonstrate the effectiveness and safety of the drug on the body. Rodents, primates, rabbits, dogs, etc. are often used in preclinical in vivo studies and they often have the advantage of similar eye structure to humans and ease of handling.
With our specialized preclinical services and various ophthalmic technology platforms, Ace Therapeutics offers clients a one-stop shop for preclinical in vivo studies, including the development of a range of animal models of glaucoma, evaluation of drug efficacy, safety, possible mechanisms of action, pharmacokinetic and pharmacodynamic properties. We are committed to efficiently conducting preclinical evaluations of new anti-glaucoma drugs to help guide drug development decisions and clinical trial design.
Services for In Vivo Study for Glaucoma
The use of animal models in glaucoma research is a powerful translational tool for the development of new therapies for human glaucoma. We should consider the strengths and limitations of various models in their design and construction, and successfully apply the results of animal experiments. We design and develop the ideal animal research model for glaucoma researchers to use to investigate and validate the scientific question or treatment program you are investigating.
Drug absorption, distribution, metabolism and elimination processes are often important factors in determining the success or failure of treatment. For glaucoma treatment, the target site of treatment and the different routes of administration are involved, which makes it very necessary to study the pharmacokinetic characteristics of glaucoma drugs in animal models. We can offer a wide range of ocular pharmacokinetic study services and customize the appropriate analytical approach to meet the specific requirements.
The drug discovery and development process are evolving in order to better treat glaucoma. To understand the effects of anti-glaucoma drugs, it is important to pharmacodynamically study the action of the drug or drug candidate in the in vivo environment. With years of experience in pharmacodynamic research and outstanding expertise, we can offer you pharmacodynamic evaluation services in animal models of glaucoma, using advanced ophthalmic techniques to explore the efficacy of specific drugs.
As a preclinical ophthalmic CRO, Ace Therapeutics provides ocular toxicology studies of glaucoma drugs, primarily including tolerability and safety assessment services. With our experienced ocular pathology team, we provide critical tolerability and safety data for various small molecules, biologics, cellular therapies, gene therapies, and other new therapies or drugs by performing specialized toxicology evaluations in various animal models.
Your Preclinical Development Partner for Glaucoma Program
- We are committed to providing the exact customer requirements for your preclinical in vivo studies through flexible solutions.
- We use state-of-the-art technology in our comprehensive network of ophthalmic facilities to customize and execute your preclinical in vivo trial and testing programs.
- We assist you from initial study design to final data reporting, providing you with reliable, reproducible results.
- We ensure that all testing meets global quality and compliance standards, thereby facilitating subsequent conversion applications.
Contact us to explore how we can provide comprehensive preclinical in vivo research services for your glaucoma program.